cetuximab indications/contra

Stem definitionDrug idCAS RN
chimeric origin 4954 205923-56-4

Description:

MoleculeDescription

Synonyms:

  • cetuximab
  • cetuximab (genetical recombination)
  • erbitux
  • C-225
  • IMC-C225
A chimeric monoclonal antibody that functions as an ANTINEOPLASTIC AGENT through its binding to the EPIDERMAL GROWTH FACTOR RECEPTOR, where it prevents the binding and signaling action of cell growth and survival factors.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

Approvals:

DateAgencyCompanyOrphan
June 29, 2004 EMA
Feb. 12, 2004 FDA IMCLONE

FDA Adverse Event Reporting System

scroll-->
MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Infusion related reaction 1630.39 54.97 457 9147 11164 3365091
Dermatitis acneiform 1599.82 54.97 308 9296 1207 3375048
Mucosal inflammation 1440.35 54.97 383 9221 7600 3368655
Rash 1429.62 54.97 659 8945 70162 3306093
Dehydration 1346.57 54.97 511 9093 33138 3343117
Diarrhoea 1342.25 54.97 714 8890 103634 3272621
Neutropenia 980.20 54.97 406 9198 32980 3343275
Vomiting 914.33 54.97 528 9076 89003 3287252
Hypomagnesaemia 892.12 54.97 224 9380 3478 3372777
Nausea 812.47 54.97 561 9043 129084 3247171
Dyspnoea 790.48 54.97 506 9098 102428 3273827
Pyrexia 738.99 54.97 445 9159 80670 3295585
Hypotension 685.50 54.97 358 9246 49156 3327099
Anaphylactic reaction 662.52 54.97 237 9367 12817 3363438
Febrile neutropenia 648.86 54.97 258 9346 18717 3357538
Stomatitis 627.19 54.97 222 9382 11630 3364625
Dysphagia 619.41 54.97 252 9352 19399 3356856
Thrombocytopenia 515.88 54.97 265 9339 35003 3341252
Malignant neoplasm progression 515.71 54.97 215 9389 17578 3358677
Anaemia 474.74 54.97 291 9313 54042 3322213
Leukopenia 474.65 54.97 196 9408 15627 3360628
Decreased appetite 472.65 54.97 264 9340 41226 3335029
Hypersensitivity 429.03 54.97 217 9387 27683 3348572
Pulmonary embolism 388.51 54.97 203 9401 27685 3348570
Chills 370.01 54.97 182 9422 21840 3354415
Pneumonia 361.41 54.97 271 9333 69872 3306383
Skin toxicity 357.01 54.97 87 9517 1177 3375078
Hypokalaemia 350.50 54.97 152 9452 13653 3362602
Sepsis 349.27 54.97 199 9405 32174 3344081
Radiation skin injury 323.76 54.97 64 9540 292 3375963

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC L01XC06 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Monoclonal antibodies
MeSH PA D000970 Antineoplastic Agents
MeSH PA D000074322 Antineoplastic Agents, Immunological
FDA EPC N0000175664 Epidermal Growth Factor Receptor Antagonist
FDA MoA N0000020010 HER1 Antagonists

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Squamous cell carcinoma of mouth indication 307502000
Malignant tumor of colon indication 363406005 DOID:219
Squamous cell carcinoma of larynx indication 405822008 DOID:2876
Squamous cell carcinoma of pharynx indication 408649007
Squamous cell carcinoma of nose indication 448930008

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

scroll-->
TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Epidermal growth factor receptor Kinase ANTIBODY BINDING Kd 9.41 IUPHAR DRUG LABEL

External reference:

scroll-->
IDSource
DB00002 DRUGBANK_ID
6882 IUPHAR_LIGAND_ID
D03455 KEGG_DRUG
4021419 VUID
N0000148833 NUI
C0995188 UMLSCUI
409400001 SNOMEDCT_US
409401002 SNOMEDCT_US
4021419 VANDF
318341 RXNORM
17947 MMSL
d05101 MMSL
N0000148833 NDFRT
008568 NDDF
N0000010539 NDFRT
CHEMBL1201577 ChEMBL_ID
PQX0D8J21J UNII
7906 INN_ID
D000068818 MESH_DESCRIPTOR_UI

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
ERBITUX HUMAN PRESCRIPTION DRUG LABEL 1 66733-948 SOLUTION 2 mg INTRAVENOUS BLA 16 sections
ERBITUX HUMAN PRESCRIPTION DRUG LABEL 1 66733-958 SOLUTION 2 mg INTRAVENOUS BLA 16 sections